“Dr. Rafal Farjo, Chief Operating Officer of eyecro, gives a seminar to Members-in-Training on Transitioning from Academia to a Start-up. At the 2013 Annual meeting of the Association for Research in vision and Ophthalmology in Seattle.”
We are proud to announce a significant breakthrough in ophthalmic care: our innovative MiDROPS® technology has been validated for safety and efficacy in its first clinical application. Data from the technology’s first clinical application is being presented at the 96th meeting of the Association for Research in Vision and Ophthalmology in Seattle, WA. Read the…
EyeCRO scientist Jarrod Harman contributed to a paper focused on X-linked juvenile retinoschisis published in Experimental Eye Research. This paper expands the mechanistic understanding of XLRS. Read the full paper here https://www.sciencedirect.com/science/article/pii/S0014483523002129?dgcid=coauthor
The 6th Ocular Diseases & Drug Discovery Conference is taking place on March 20-21, 2014 in San Diego, CA. The conference continues to offer presentations on novel and innovative therapeutics in ocular drug development and discovery. This forum allows for excellent networking, the exchange of ideas, and sharing of challenges; all with a united common…
Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model. Click here to read more
EyeCRO is thrilled to announce the first clinical application of our groundbreaking MiDROPS® technology.
Locations
Oklahoma City — Headquarters
5301 N. Beverly Drive
Oklahoma City, OK 73105
Ann Arbor
2725 S. Industrial Hwy, Suite 150
Ann Arbor, MI 48104
Credentials
AAALAC International
Full accreditation — both facilities
Signatory
© 2026 EyeCRO. All rights reserved.
eyecro.com